🇺🇸 FDA
Patent

US 10034936

Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein

granted A61KA61K2039/505A61K39/29

Quick answer

US patent 10034936 (Method of inducing a cross-reactive HIV-1 immune response by administering a composition comprising the GBV-C E2 protein) held by THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRS
Grant date
Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2039/505, A61K39/29, A61P, A61P31/18